GLP-1 Receptor Agonists: From Research Compound to Clinical Supply

GLP-1 receptor agonists represent one of the most significant developments in metabolic medicine in recent decades. Originally developed for type 2 diabetes management, these compounds have demonstrated substantial efficacy in weight reduction and are now among the most widely discussed molecules in both clinical and research contexts.

Receptor Biology

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the small intestine in response to nutrient ingestion. It acts on GLP-1 receptors in the pancreas to stimulate insulin secretion and suppress glucagon release, and on receptors in the hypothalamus to reduce appetite and promote satiety. GLP-1 receptor agonists are synthetic analogues designed to mimic and extend these effects.

Semaglutide, Tirzepatide, and Retatrutide

Semaglutide is a GLP-1 receptor agonist with a half-life of approximately one week, enabling once-weekly dosing. It has demonstrated weight reductions of 15–17% in clinical trials at therapeutic doses. Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown weight reductions of up to 22% in the SURMOUNT trial programme. Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, has shown reductions of up to 24% in phase 2 trials.

Supply Considerations

These compounds are complex peptides with specific synthesis and formulation requirements. Purity specifications should be 98% or above by HPLC, with mass spectrometry confirmation. Given the clinical significance of these molecules, batch-specific COAs from independent laboratories are essential. Professional buyers should also be aware of the regulatory status of these compounds in their jurisdiction — while semaglutide and tirzepatide are licensed medicines in the UK, their supply as research compounds is subject to specific regulatory considerations.